OncoSec Medical, Inc. (NASDAQ: ONCS) Starts Presentation at LD Micro 2017 Invitational
OncoSec Medical (NASDAQ: ONCS) is a biotech company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse®, for the treatment of cancer. ImmunoPulse® is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents. In phase I and II clinical trials, ImmunoPulse® IL-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various solid tumors as well as the potential to initiate a systemic immune response. OncoSec's lead program, ImmunoPulse® IL-12, is currently in clinical development for several indications, including metastatic melanoma, and triple-negative breast cancer. In addition to ImmunoPulse® IL-12, the Company…